Larimar Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a quarterly report; financial comparisons below are year-over-year. Clinical and financing updates from 2024 are subsequent events, not 2023 results.
Business context
Larimar is a clinical-stage biotechnology company developing treatments for rare diseases. Its lead and only clinical-stage candidate is nomlabofusp, an investigational subcutaneous fusion protein intended to deliver frataxin (FXN) to mitochondria in patients with Friedreich’s ataxia (FA). The company has no commercial products or product revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | None | None | No commercial revenue |
| Research and development expense | $27.7 million | $24.3 million | Up $3.4 million |
| General and administrative expense | $14.1 million | $12.3 million | Up $1.8 million |
| Total operating expenses | $41.8 million | $36.5 million | Up $5.2 million |
| Other income, net | $4.8 million | $1.2 million | Increase primarily reflected higher investment balances and yields |
| Net loss | $36.9 million | $35.4 million | Loss widened $1.6 million |
| Basic and diluted loss per share | $0.84 | $1.37 | Lower loss per share, with higher weighted-average shares |
| Net cash used in operating activities | $33.5 million | $27.6 million | Use increased $5.9 million |
Margins are not meaningful because Larimar had no revenue. At year-end, cash and cash equivalents were $26.7 million and marketable securities were $60.0 million, totaling $86.8 million; restricted cash was an additional $1.3 million. Current assets were $90.2 million and current liabilities $9.5 million. No financial borrowings are disclosed; reported lease liabilities totaled $5.5 million, including current and long-term amounts.
Total assets were $95.9 million versus $126.4 million in 2022, while stockholders’ equity was $81.7 million versus $110.9 million. The accumulated deficit was $188.6 million. Operating cash use increased with development activity; investing cash flows primarily reflected purchases and maturities or sales of marketable securities.
Material changes and subsequent financing
- Operating expenses rose 14% year over year. R&D expense increased with nomlabofusp clinical development, regulatory and bioanalysis work, and personnel; lower drug-manufacturing costs partly offset those increases.
- In February 2024, Larimar sold 19.7 million shares at $8.74 per share, receiving approximately $161.6 million in net proceeds. Management expects those proceeds plus year-end cash, cash equivalents and marketable securities to fund operations into 2026. The offering materially increased the share count; 63.8 million common shares were outstanding as of March 12, 2024.
- For 2023, financing cash flow was negligible; the principal financing inflow in 2022 was a public offering that generated $75.3 million net.
Outlook, development, and key risks
- Clinical status: The FDA partial clinical hold remained in place. The FDA permitted the 50 mg Phase 2 dose-exploration cohort and an open-label extension (OLE) at 25 mg daily; higher OLE doses and further clinical development remain subject to FDA review.
- Post-year-end Phase 2 update: In February 2024, Larimar reported positive top-line results from the completed four-week, placebo-controlled study. The 25 mg and 50 mg cohorts showed dose-dependent FXN increases in skin and buccal cells after 14 days of daily dosing. FXN levels declined in magnitude after dosing changed to every other day. The 50 mg cohort’s skin levels reportedly rose from below 17% of healthy-volunteer levels at baseline to 33%–59% after 14 days.
- Safety: In the 28-person Phase 2 study, 19 participants received nomlabofusp and nine placebo. No serious adverse events were reported; one severe allergic reaction in the 25 mg cohort resolved with standard treatment, and the participant withdrew. Injection-site reactions were the most common reported events.
- Next milestones: Larimar reported initiating the OLE in January 2024, with the first participant dosed in March 2024; initial OLE data were expected in the fourth quarter of 2024. It is pursuing accelerated approval using FXN levels as a proposed surrogate endpoint, supported by OLE safety, pharmacodynamic and clinical information and additional nonclinical data. The company targeted a BLA submission in the second half of 2025, but FDA acceptance of the surrogate-endpoint approach and the timeline are uncertain.
- Principal risks: The program’s dependence on FDA decisions and the unresolved partial hold; uncertainty about long-term daily-dose safety and whether FXN changes predict clinical benefit; small FA patient populations and competition, including approved omaveloxolone; reliance on third-party manufacturers and the need to scale production; and continued losses and potential need for additional capital. The company has not manufactured nomlabofusp at commercial scale.
- Nomlabofusp has U.S. and European orphan designations, U.S. Fast Track and Rare Pediatric Disease designations, and European PRIME designation. These designations do not guarantee approval or a faster review. Licensed patents covering nomlabofusp have varying expiry dates, including key U.S. patents cited as expiring in 2024, 2025 and 2040.
Management expects continued operating losses and increasing development expenses. The filing reports no material pending litigation. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the auditor did not provide an opinion on internal control effectiveness.
Important facts for investors to verify
- Whether the FDA will ease the partial clinical hold, permit OLE dose escalation, and allow additional trials.
- Whether longer-term OLE results support safety, tolerability, sustained FXN increases and a relationship to clinical benefit; verify the Q4 2024 data timing and actual findings.
- Whether FDA accepts FXN as a surrogate endpoint for accelerated approval and what evidence, confirmatory trial and manufacturing requirements it imposes.
- Cash burn, investment balances and the assumptions behind management’s runway estimate into 2026, including the effect of development delays or increased spending.
- The dilution from the February 2024 offering and subsequent share count, as well as the potential effect of equity compensation and future financing.
- Manufacturing readiness, clinical supply reliability, and progress on the lyophilized formulation and commercial-scale process.